Published in final edited form as:

Tetrahedron. 2014 September 2; 70(35): 5928–5933. doi:10.1016/j.tet.2014.06.021.

Total Synthesis of Calothrixins A and B via Oxidative Radical Reaction of Cyclohexenone with Aminophenanthridinedione

Su Xu^a, Thao Nguyen^a, Irene Pomilio^c, Maria C. Vitale^c, and Sadanandan E. Velu^{*,a,b}

^aDepartment of Chemistry, University of Alabama at Birmingham, 901 14th Street South, Birmingham, AL 35294-1240, USA

^bComprehensive Cancer Center, University of Alabama at Birmingham, 1720 2nd Avenue South, Birmingham, AL 35294-3300, USA

^cExchange program students from the University of “G. d’Annunzio” Chieti-Pescara, Via dei Vestini 66013, Chieti, Italy.

Abstract

Bioactive indolo[3,2-*j*]phenanthridine alkaloids, calothrixin B and its N-oxide derivative calothrixin A have been synthesized via an oxidative free radical reaction. calothrixin B is generated from the commercially available 2,4,5-trimethoxybenzaldehyde in only 7 steps. The key step in this synthesis is the Mn(OAc)₃ mediated oxidative free radical reaction of 9-(benzylamino)phenanthridine -7,10-dione with cyclohexenone to form 12-benzyl-12*H*-indolo[3,2-*j*]phenanthridine-7,13-dione.

Keywords

Calothrixin; Total Synthesis; Oxidative; Free Radical; Aminophenanthridinedione

Introduction

Natural products have traditionally played a major role in drug discovery by serving as the source for many of the earliest medicines.¹ In spite of the scientific advancements and the promise of alternative drug discovery strategies in the recent decades, there is still a shortage of drug leads progressing into clinical trials especially in the areas of oncology, immunosuppression, and metabolic diseases.² Natural products continue to play a major role in providing leads particularly in these areas as shown by a recent review published by Newman and Cragg which summarizes natural product derived drugs over past 30 years

© 2014 Elsevier Ltd. All rights reserved.

*Corresponding author. svelu@uab.edu (S.E. Velu), Phone: (205) 975 2478, Fax: (205) 934 2543..

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supplementary material

Copies of ¹H NMR, ¹³C NMR spectra of all compounds are available as Supplementary Material.

(1981-2010).³ Even though many natural products exhibit potent biological activities, their systematic biological evaluation is precluded because they are often isolated in very minute quantities. Further, natural products are known to have unique chemical structures which provide challenging synthetic targets for organic chemists. For these reasons, development of new synthetic methods for natural products remains as a very important research area.

Calothrixin B and its N-oxide derivative, calothrixin A (Fig. 1) are two bioactive metabolites isolated from the cyanobacteria *Calothrix* in 1999.⁴ They are also known as indolophenanthridines because they contain the unusual pentacyclic indolo[3,2-*j*]phenanthridine ring system. This ring system consists of indole, quinone, and quinoline moieties and is unique amongst natural products (Fig. 1).

Calothrixins possess a wide array of biological activities that are of interest to medicinal chemists. They display nanomolar antiproliferative activity against certain human cancer cell lines such as human cervical cancer cell, HeLa⁴⁻⁵, CEM leukemia cells,⁶ and human Jurkat cancer cells.⁷ Furthermore, calothrixins A and B act as a new class of human DNA topoisomerase I poisons. They stabilize the topoisomerase I-DNA binary complex to prevent DNA religation and cause DNA damage which results in apoptosis.⁸ In addition, calothrixin A binds to DNA quadruplex to inhibit DNA replication and DNA directed RNA synthesis resulting in impaired protein synthesis and cell death.⁹ They also exhibit *in vitro* antiparasitic activity against chloroquine resistant strains of *Plasmodium falciparum*, which is the causative organism for malaria.⁴ These biological activities make calothrixins the potential lead compounds for anticancer and antiparasitic drug discovery. Due to their unique structural features and potent bioactivity, calothrixins are notable synthetic targets.⁴⁻⁹ The first total synthesis of calothrixins was reported by Kelly, using an *o*-lithiation strategy.¹⁰ Several other syntheses of calothrixins have also been reported exploring different synthetic strategies such as metallations,¹¹ hetero Diels-Alder,¹² Friedel-Crafts acylation reaction,^{11a, 13} etc. A few other syntheses of calothrixins have also been reported.¹⁴

As a part of our interest in deriving lead drug molecules from natural products,¹⁵ we have been particularly interested in developing a shorter and a better yielding synthesis of calothrixins. Majority of the reported calothrixin syntheses are focused on the formation of the middle benzoquinone ring between the indole and quinoline units as the last step. Our synthetic approach relies on the construction of the indole ring on to a phenanthridine dione via a novel oxidative free radical reaction mediated by Mn(OAc)₃. The method of Mn(OAc)₃ mediated oxidative reaction of 2-cyclohexenone with quinones was originally developed by Chuang *et al.*¹⁶ None of the existing reports of calothrixin synthesis utilizes the late stage indole construction strategy and thus our synthetic approach is unique and different.

Research literature published in the recent three decades highlights the importance of oxidative free radical reactions mediated by transition metals. These reactions result in intermolecular / intramolecular formation of carbon-carbon bonds through transient electrophilic carbon radicals¹⁷ and are most commonly promoted by transition metal compounds. Manganese triacetate (Mn(OAc)₃) and ceric (IV) ammonium nitrate (CAN) are

the most commonly used and efficient catalysts for the oxidative reaction between 1,3-diketones and aminoquinones. The mechanism for this type of oxidative free radical reactions has been reported.^{16, 17b, 17e}. $\text{Mn}(\text{OAc})_3$ and CAN promoted oxidative free radical cyclizations have also been used extensively in the synthesis of naphthaquinones, which is an important skeleton of natural products.¹⁸ The synthesis of several interesting compounds in our laboratory takes advantage of oxidative free radical reactions. Bispyrroloquinone, and bispyrroloiminoquinone ring systems were synthesized via CAN mediated oxidative free radical reaction of 1,3-dicarbonyl compounds with aminoquinones¹⁹ while Zyzzyanones were synthesized using $\text{Mn}(\text{OAc})_3$ mediated oxidative free radical reactions.²⁰ Apart from being a powerful tool to construct polycyclic ring systems, these reactions are generally high yielding and are relatively easy to perform. We report herein the synthesis of calothrixins taking advantage of an oxidative radical reaction between cyclohexenone and an aminophenanthridinedione derivative.

Results and Discussion

Our retrosynthetic analysis for calothrixin B utilizes an oxidative free radical reaction strategy as outlined in Scheme 1. We envisaged that the intermediate compound **6** for calothrixin synthesis could be prepared by the amination of 2,4,5-trimethoxybenzaldehyde (**8**) with *ortho*-iodoaniline (**7**) followed by a palladium catalyzed coupling. Oxidation of compound **6** with CAN can afford the corresponding methoxy quinone **5**, which could be aminated to form the aminoquinone **4**. Oxidative free radical reaction of the aminoquinone **4** with cyclohexenone (**3**) in the presence of $\text{Mn}(\text{OAc})_3$ could give calothrixin B, which could be further oxidized with *m*-CPBA to form calothrixin A. Construction of the indole ring to the phenanthridine dione using cyclohexenone and $\text{Mn}(\text{OAc})_3$ is the novel aspect of our calothrixin synthesis.

Our investigation started with the synthesis of the key intermediate compound **5** as outlined in Scheme 2. Reductive amination of commercially available 2,4,5-trimethoxybenzaldehyde (**8**) with *ortho*-iodoaniline (**7**) in the presence of NaCNBH_3 in a mixture of MeOH and acetic acid gave the compound **9** in 99% yield. In order to avoid potential complications, the NH group present in compound **9** was protected as an acetyl amide. This was achieved by the treatment of compound **9** with Ac_2O in the presence of catalytic amount of DMAP at room temperature for 15 hours to form compound **10** in 85% yield. Then the acetyl protected compound **10** was treated with $\text{Pd}(\text{OAc})_2$, PPh_3 , and K_2CO_3 in DMF at reflux condition for 7 hours to generate the cyclized product **11** in 97% yield.

Complications occurred with the assignment of CH_2 proton signal within the ^1H -NMR spectra of compound **11** as seen by the broad multiplet ranging from 4.2 to 5.5 ppm. These protons were almost invisible in the spectra. This might be due to the fact that the molecule exists as a pair of amide rotamers that are in dynamic equilibrium. In order to confirm the structure of compound **11** unambiguously, we recorded a ^1H -NMR in $\text{DMSO}-d_6$ at 90 °C. The CH_2 proton signal was clearly visible as a sharp singlet in the high temperature NMR, which confirms the structure of compound **11**. This might be due to the faster equilibration of the amide rotamers at higher temperature. Compound **11** was then oxidized using CAN in a mixture of CH_3CN , chloroform and water to afford the quinone **5** in 70% yield.

Surprisingly, the deacetylation and aromatization of the N containing ring also occurred under the same reaction conditions.

Conversion of quinone **5** to calothrixins A and B is outlined in Scheme 3. In order to construct the indole ring on to the quinone **5** by oxidative free radical reaction we needed to substitute the methoxy group in **5** with an amino functionality. We chose a benzyl amino group in this case as the benzyl group could serve as a protecting group and could be removed at the end of the synthesis. Reaction of the quinone **5** with benzyl amine in anhydrous MeOH under reflux conditions resulted in the formation of benzylamino phenanthridine dione **12** in 91% yield. Then the oxidative free radical reaction was performed by refluxing the mixture of benzylamino phenanthridine dione **12** and cyclohexenone in the presence of Mn(OAc)₃ in anhydrous CH₃CN for three days to afford compound **13** in 92% yield. Finally, the debenzilation of compound **13** was carried out by following a previously reported literature procedure using AlCl₃ and anhydrous benzene to furnish calothrixin B (**2**) in 40 % yield.^{12b} In order to improve the yield of this step, we attempted other debenzilation reaction conditions such as H₂ in the presence of Pd/C or Pd black/HCOONH₄. But, these reactions resulted in lower yields than what we obtained with AlCl₃. Calothrixin B (**2**) was oxidized to calothrixin A (**1**) in 99 % yield using *m*-CPBA in DCM following the literature procedure.¹⁰

Based on the previous literature reports on the mechanism of oxidative free radical reactions,^{16, 17e, 21} a plausible mechanism for the conversion of compound **12** to **13** is outlined in Scheme 4. Initiation of the reaction occurs with the interaction of Mn(OAc)₃ with 2-cyclohexenone to generate the radical **14** by a one-electron oxidation. Intermolecular addition of radical **14** to the quinone **12** generates another radical **15**. Oxidation of **15** by another molecule of Mn(OAc)₃ produces the corresponding cation **16**, which is deprotonated to form the intermediate **17**. Intramolecular condensation of **17** forms the compound **18** which up on aromatization yields the product **13**.

Conclusions

In summary, we have described a new and efficient synthesis of calothrixin A and B with good overall yields. Synthesis of calothrixin B was achieved from 2,4,5-trimethoxybenzaldehyde in only 7 steps. This novel synthetic strategy involves the construction of an indole ring on to a phenanthridine-7,10-dione to form the calothrixin core. The key step in this synthesis is Mn(OAc)₃ mediated oxidative free radical reaction of 9-(benzylamino)phenanthridine -7,10-dione to form 12-benzyl-12*H*-indolo[3,2-*j*]phenanthridine-7,13-dione in excellent yield.

Experimental Section

General Methods for Synthesis

Solvent evaporations were carried out *in vacuo* using a rotary evaporator. Thin layer chromatography (TLC) was performed on silica gel plates with fluorescent indicator (Dynamic Adsorbents, Inc., Aluminum backed TLC, 20 X 20 cm F-254, 200 μm). Spots were visualized by UV light (254 and 365 nm). Purification by column and flash

chromatography was carried out using silica gel (32-63 μm) from Dynamic Absorbent in the solvent systems indicated. The amount (weight) of silica gel for column chromatography was in the range of 50-100 times the amount (weight) of the crude compounds being separated. Melting points were determined on a Mel-Temp II melting point apparatus and are uncorrected. The NMR spectra were recorded on Bruker DPX 300 spectrometer. Chemical shifts are reported in ppm relative to TMS or CDCl_3 as internal standard. The values of chemical shifts (δ) and coupling constants J were given in parts per million and in Hz, respectively. Mass spectra were recorded on a MicroMass Platform LCC instrument. HRMS were obtained on a Waters AutoSpec-UltimaTM NT mass spectrometer with an EI source. Anhydrous solvents used for reactions were purchased in Sure-SealTM bottles from Aldrich chemical company. Other reagents were purchased from Aldrich, Lancaster or Fisher chemical companies and used as received.

***N*-(2,4,5-trimethoxybenzyl)-2-iodobenzenamine (9)**

To a stirred solution of *o*-iodoaniline **7** (3.85 g, 17.5 mmol) in MeOH (50 mL), 2,4,5-trimethoxybenzaldehyde **8** (3.45 g, 17.5 mmol) and a solution of acetic acid (1.58 g, 26.3 mmol) in MeOH (10 mL) were added and the reaction mixture was stirred at rt under N_2 atm for 30 min. The reaction mixture was cooled to 0 $^\circ\text{C}$ using an ice bath and NaCNBH_3 (1.44 g, 22.8 mmol) was added in 4 portions over a period of 15 min and the solution was stirred for another 20 min at 0 $^\circ\text{C}$. The reaction mixture was then stirred at rt for 1 h. TLC examination (30% EtOAc in hexanes) revealed that the reaction was complete. Reaction mixture was then quenched with sat. NaHCO_3 (100 mL) and the solvent was removed to obtain a brown residue. The residue was diluted with water (30 mL) and filtrated to afford the pure *N*-(2,4,5-trimethoxybenzyl)-2-iodobenzenamine **9** (6.95 g, 99%); Mp: 84-86 $^\circ\text{C}$; ^1H NMR (CDCl_3) δ 3.80 (s, 3H), 3.87 (s, 3H), 3.90 (s, 3H), 4.32 (d, J = 5.5 Hz, 2H), 4.63 (t, J = 5.5 Hz, 1H), 6.43 (t, J = 7.6 Hz, 1H), 6.56 (s, 1H), 6.63 (d, J = 8.4 Hz, 1H), 6.86 (s, 1H), 7.17 (t, J = 7.6 Hz, 1H), 7.66 (d, J = 8.1 Hz, 1H); ^{13}C NMR (CDCl_3) δ 43.6, 56.5 (2C), 57.0, 85.8, 97.9, 111.5, 113.5, 118.3, 119.0, 129.6, 139.2, 143.3, 147.7, 149.2, 151.9; MS (ES^+) m/z 400 ($\text{M} + \text{H}$) and HRMS calcd for $\text{C}_{16}\text{H}_{18}\text{INO}_3$ 399.0331, found 399.0343.

***N*-(2,4,5-trimethoxybenzyl)-*N*-(2-iodophenyl)acetamide (10)**

To a stirred solution of *N*-(2,4,5-trimethoxybenzyl)-2-iodobenzenamine **9** (6.42 g, 16.1 mmol) in acetic anhydride (35 mL), a cat amount of DMAP (196 mg, 1.6 mmol) was added and the reaction mixture was stirred at rt under N_2 atm for 15 h. TLC examination (50% EtOAc in hexanes) revealed that the reaction was complete. The solvent was removed and the residue was dissolved in EtOAc (400 mL), which was washed with water (3×100 mL) and brine (1×100 mL) and dried over Na_2SO_4 . The drying agent was filtered off and the filtrate was concentrated on a rotary evaporator to afford the pure *N*-(2,4,5-trimethoxybenzyl)-*N*-(2-iodophenyl)acetamide **10** (6.04 g, 85%); Mp: 126-127 $^\circ\text{C}$; ^1H NMR (CDCl_3) δ 1.79 (s, 3H), 3.41 (s, 3H), 3.79 (s, 3H), 3.83 (s, 3H), 4.36 (d, J = 13.8 Hz, 1H), 5.28 (d, J = 13.8 Hz, 1H), 6.33 (s, 1H), 6.73 (d, J = 7.8 Hz, 1H), 6.91 (s, 1H), 6.98 (t, J = 7.2 Hz, 1H), 7.17 (t, J = 7.5 Hz, 1H), 7.87 (d, J = 7.8 Hz, 1H); ^{13}C NMR (CDCl_3) δ 23.1, 44.9, 56.2 (2C), 56.7, 97.2, 100.6, 115.3, 116.6, 129.0, 129.5, 130.6, 139.8, 143.1, 144.8, 149.3, 152.4, 170.1; MS (ES^+) m/z 442 ($\text{M} + \text{H}$) and HRMS calcd for $\text{C}_{18}\text{H}_{20}\text{INO}_4$ 441.0437, found 441.0432.

1-(7,9,10-trimethoxyphenanthridin-5(6*H*)-yl)ethanone (11)

To a stirred solution of *N*-(2,4,5-trimethoxybenzyl)-*N*-(2-iodophenyl)acetamide **10** (300 mg, 0.68 mmol) in anhyd DMF (5 mL), PPh₃ (52 mg, 0.20 mmol), anhyd K₂CO₃ (136 mg, 0.99 mmol) and Pd(OAc)₂ (15 mg, 0.06 mmol) were added and the reaction mixture was refluxed under N₂ atm for 7 h. TLC examination (50% EtOAc in hexanes) revealed that the reaction was complete. The reaction mixture was cooled to rt and filtered through celite and washed with EtOAc (3 × 50 mL). The combined filtrates were washed with water (3 × 50 mL) and brine (1 × 50 mL) and dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated to afford the crude product, which was purified by column chromatography over Si gel (20 × 2 cm) using EtOAc / hexanes (1:3) as eluent to afford the pure 1-(7,9,10-trimethoxyphenanthridin-5(6*H*)-yl)ethanone **11** (210 mg, 97%); Mp: 173-175 °C; ¹H NMR (CDCl₃) δ 2.15-2.39 (m, 3H), 3.68 (s, 3H), 3.84 (s, 3H), 3.90 (s, 3H) 4.14-5.52 (brs, 2H), 6.50 (s, 1H), 7.12-7.34 (m, 3H), 8.38-8.50 (m, 1H); ¹H NMR (90 °C, DMSO-*d*₆) δ 2.15 (s, 3H), 3.71 (s, 3H), 3.91 (s, 3H), 3.94 (s, 3H), 4.72 (s, 2H), 6.83 (s, 1H), 7.31-7.43 (m, 2H), 7.53 (d, *J* = 7.7 Hz, 1H), 8.35 (d, *J* = 7.7 Hz, 1H); ¹³C NMR (CDCl₃) δ 22.2, 39.1, 56.1, 56.3, 60.5, 97.0, 117.9, 124.5, 125.7, 126.0, 127.7, 128.3, 128.7, 138.7, 140.8, 151.4, 152.9, 169.0; MS (ES+) *m/z* 314 (M + H) and HRMS calcd for C₁₈H₁₉NO₄ 313.1314, found 313.1315.

9-Methoxyphenanthridine-7,10-dione (5)

To a stirred solution of 1-(7,9,10-trimethoxyphenanthridin-5(6*H*)-yl)ethanone **11** (400 mg, 1.3 mmol) in a mixture of CH₃CN (100 mL) and CHCl₃ (5mL), a solution of CAN (2.79 g, 5.1 mmol) in water (100 mL) was added. The reaction mixture was stirred at rt for 7 h. TLC examination (50% EtOAc in hexanes) revealed that the reaction was complete. CH₃CN was removed under reduced pressure and the residue obtained was extracted with CHCl₃ (4 × 100 mL). The combined organic layers were washed with water (3 × 100 mL), brine (2 × 100 mL) and dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated to obtain the crude product, which was purified by column chromatography over Si gel (20 × 2 cm) using CHCl₃ as eluent to afford the pure 9-methoxyphenanthridine-7,10-dione **5** (214 mg, 70%); Mp: 243-245 °C; ¹H NMR (CDCl₃) δ 3.97 (s, 3H), 6.20 (s, 1H), 7.81 (t, *J* = 7.8 Hz, 1H), 7.89 (t, *J* = 7.2 Hz, 1H), 8.21 (d, *J* = 8.7 Hz, 1H), 9.41 (d, *J* = 8.4 Hz, 1H), 9.66 (s, 1H); ¹³C NMR (CDCl₃) δ 57.0, 107.9, 122.3, 122.9, 127.5, 130.7, 131.0, 131.1, 132.1, 147.8, 152.1, 160.7, 183.0, 185.1; MS (ES+) *m/z* 240 (M + H) and HRMS calcd for C₁₄H₉NO₃ 239.0582, found 239.0592.

9-(Benzylamino)phenanthridine-7,10-dione (12)

To a stirred solution of 9-methoxyphenanthridine-7,10-dione **5** (200 mg, 0.83 mmol) in MeOH (50 mL), a solution of benzyl amine (358 mg, 3.3 mmol) in MeOH (25 mL) was added in 2 portions over 5 h and the reaction mixture was refluxed under N₂ atm for another 6 h. TLC analysis (50% EtOAc in hexanes) revealed that the reaction was complete. The solvent was removed by a rotary evaporator to afford the crude product, which was purified by column chromatography over Si gel (20 × 2 cm) using EtOAc / hexanes (1:1) as eluent to afford the pure 9-(benzylamino)phenanthridine-7,10-dione **12** (239 mg, 91%); Mp: 183-185 °C; ¹H NMR (CDCl₃) δ 4.43(d, *J* = 6.0 Hz, 2H), 5.82 (s, 1H), 6.30 (brs, 1H), 7.28-7.48 (m,

5H), 7.73-7.90 (m, 2H), 8.20 (d, $J = 8.1$ Hz, 1H), 9.37 (d, $J = 8.4$ Hz, 1H), 9.71 (s, 1H); ^{13}C NMR (CDCl_3) δ 47.3, 100.2, 122.3, 124.1, 127.0, 127.9, 128.6, 129.4, 130.2, 130.8 (2C), 131.5, 135.9, 148.2, 148.52, 151.6, 183.1, 185.0; MS (ES^+) m/z 315 ($\text{M} + \text{H}$) and HRMS calcd for $\text{C}_{20}\text{H}_{14}\text{N}_2\text{O}_2$ 314.1055, found 314.1067.

12-benzyl-12*H*-indolo[3,2-*j*]phenanthridine-7,13-dione (**13**)

To a stirred solution of 9-(benzylamino)phenanthridine-7,10-dione **12** (12 mg, 0.04 mmol) in CH_3CN (16 mL), $\text{Mn}(\text{OAc})_3 \cdot 2\text{H}_2\text{O}$ (142 mg, 0.53 mmol) and a solution of 2-cyclohexen-1-one **3** (15 mg, 0.15 mmol) in CH_3CN (4 mL) were added. The reaction mixture was refluxed under N_2 atm for 3 days. TLC examination (30% EtOAc in hexanes) revealed that the reaction was complete. The reaction mixture was then allowed to attain rt and the solvent was removed under reduced pressure. The residue obtained was then dissolved in EtOAc (50 mL) and washed with saturated NaHSO_3 (3×30 mL), water (3×30 mL) and brine (2×25 mL) and dried over Na_2SO_4 . The drying agent was filtered off and the filtrate was concentrated to afford the crude product, which was purified by column chromatography over Si gel using EtOAc / hexanes (1:19) as eluent to afford the pure 12-benzyl-12*H*-indolo[3,2-*j*]phenanthridine-7,13-dione **13** (14 mg, 92 %); Mp: 255-257 °C; ^1H NMR (CDCl_3) δ 6.02 (s, 2H), 7.17-7.37 (m, 5H), 7.38-7.51 (m, 3H), 7.74 (t, $J = 8.4$ Hz, 1H), 7.83(t, $J = 6.9$ Hz, 1H), 8.18 (d, $J = 7.5$ Hz, 1H), 8.43-8.50 (m, 1H), 9.53 (d, $J = 8.4$ Hz, 1H), 9.80 (s, 1H); ^{13}C NMR (CDCl_3) δ 48.8, 111.8, 118.0, 123.4, 123.6, 124.2, 124.8, 125.4, 126.8, 127.9, 128.1, 128.2, 129.1, 130.3, 130.6, 131.6, 133.6, 135.4, 136.5, 140.4, 148.2, 152.5, 181.3, 182.3; MS (ES^+) m/z 389 ($\text{M} + \text{H}$) and HRMS calcd for $\text{C}_{26}\text{H}_{16}\text{N}_2\text{O}_2$ 388.1212, found 388.1218.

Calothrixin B (**1**)

To a solution of 12-benzyl-12*H*-indolo[3,2-*j*]phenanthridine-7,13-dione **13** (10 mg, 0.03 mmol) in anhyd benzene (10 mL), AlCl_3 (17 mg, 0.13 mmol) was added and the reaction mixture was refluxed for 5 h. TLC examination (20 % EtOAc in hexanes) revealed that the reaction was complete. The reaction mixture was then allowed to attain rt, quenched with water (10 mL), and extracted by DCM (2×30 mL). The combined organic layers were dried over Na_2SO_4 . The drying agent was filtered off and the filtrate was concentrated on a rotary evaporator to afford the crude product, which was purified by column chromatography over Si gel (20×2 cm) using EtOAc/hexanes (1:9) as eluent to afford the pure calothrixin B (3 mg, 40 %); Mp: 298-300 °C; ^1H NMR ($\text{DMSO}-d_6$) δ 7.42 (t, $J = 8.1$ Hz, 1H), 7.50 (t, $J = 8.4$ Hz, 1H), 7.63 (d, $J = 8.1$ Hz, 1H), 7.89 (t, $J = 6.9$ Hz, 1H), 7.97 (t, $J = 6.9$ Hz, 1H), 8.19 (m, 2H), 9.59 (d, $J = 8.7$ Hz, 1H), 9.63(s, 1H), 13.18 (bs, 1H); ^{13}C NMR ($\text{DMSO}-d_6$) δ 113.9, 115.5, 122.3, 122.6, 123.3, 124.3, 124.9, 127.2, 129.8, 130.2, 131.6 (2C), 132.6, 138.0, 138.4, 147.5, 151.2, 180.4, 180.8; MS (ES^+) m/z 299 ($\text{M} + \text{H}$) and HRMS calcd for $\text{C}_{19}\text{H}_{10}\text{N}_2\text{O}_2$ 298.0742, found 298.0745.

Calothrixin A (**2**)

To a suspension of calothrixin B (5 mg, 0.02 mmol) in DCM (10 mL), under nitrogen, *m*-CPBA (77 %, 13 mg, 0.08 mmol) in DCM (10 mL) was added and the reaction mixture was refluxed overnight. TLC (50 % EtOAc in hexanes) examination revealed that the reaction

was complete. The reaction mixture was diluted with DCM (50 mL) to afford a red orange solution, which was washed with saturated K_2CO_3 (3×15 mL), water (3×15 mL), brine (15 mL) and dried over Na_2SO_4 . The drying agent was filtered off and the filtrate was concentrated on a rotary evaporator to afford the crude product, which was purified by column chromatography over Si gel (20×2 cm) using EtOAc / hexanes (3:17) as eluent to afford the pure calothrixin A (5 mg, 99 %); Mp: 283-285 °C; 1H NMR (DMSO- d_6) δ 7.38 (t, $J = 7.2$ Hz, 1H), 7.46 (t, $J = 7.8$ Hz, 1H), 7.61 (d, $J = 7.8$ Hz, 1H), 7.99-7.97 (m, 2H), 8.13 (d, $J = 7.5$ Hz, 1H), 8.61 (d, $J = 9.9$ Hz, 1H), 8.89 (s, 1H), 9.68 (d, $J = 9.3$ Hz, 1H), 13.22 (s, 1H); ^{13}C NMR (DMSO- d_6) δ 114.0, 115.1, 119.1, 121.9, 122.0, 123.4, 124.5, 126.8, 127.0, 128.1, 129.9, 131.8, 131.9, 132.0, 138.1, 138.7, 143.1, 177.8, 178.3; MS (ES+) m/z 315 (M + H) and HRMS calcd for $C_{19}H_{10}N_2O_3$ 314.0691, found 314.0701.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

Authors also wish to acknowledge the financial support by the Collaborative Programmatic Development Grant from the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center. Beginning Grant-in-Aid (AHA0865323E) from American Heart Association Greater Southeast Affiliate is also acknowledged. Authors would like to thank Ms. Bhavitavya Nijampatnam for the proof reading of this manuscript.

References

1. a Brown DG, Lister T, May-Dracka TL. *Bioorg. Med. Chem. Lett.* 2014; 24:413. [PubMed: 24388805] b Camp D, Davis RA, Evans-Illidge EA, Quinn RJ. *Future Med. Chem.* 2012; 4:1067. [PubMed: 22709251] c Cragg GM, Newman DJ. *Expert Opin. Invest. Drugs.* 2000; 9:2783. d Newman DJ, Cragg GM, Snader KM. *Nat. Prod. Rep.* 2000; 17:215. [PubMed: 10888010] e Ojima I. J. *Med. Chem.* 2008; 51:2587. [PubMed: 18393400]
2. Butler MS. *Nat. Prod. Rep.* 2005; 22:162. [PubMed: 15806196]
3. Newman DJ, Cragg GM. *J. Nat. Prod.* 2012; 75:311. [PubMed: 22316239]
4. Rickards RW, Rothschild JM, Willis AC, de Chazal NM, Kirk J, Kirk K, Saliba KJ, Smith GD. *Tetrahedron.* 1999; 55:13513.
5. Bernardo PH, Chai CL, Le Guen M, Smith GD, Waring P. *Bioorg. Med. Chem. Lett.* 2007; 17:82. [PubMed: 17098429]
6. a Khan QA, Lu J, Hecht SM. *J. Nat. Prod.* 2009; 72:438. [PubMed: 19203291] b Costa M, Costa-Rodrigues J, Fernandes MH, Barros P, Vasconcelos V, Martins R. *Marine drugs.* 2012; 10:2181. [PubMed: 23170077]
7. Chen XX, Smith GD, Waring P. *J. Appl. Phycol.* 2003; 15:269.
8. a Doan NT, Rickards RW, Rothschild JM, Smith GD. *J. Appl. Phycol.* 2000; 12:409. b Doan NT, Stewart PR, Smith GD. *FEMS Microbiol. Lett.* 2001; 196:135. [PubMed: 11267769]
9. Owen EA, Keniry MA. *Aus. J. Chem.* 2009; 62:1544.
10. Kelly TR, Zhao Y, Cavero M, Torneiro M. *Org. Lett.* 2000; 2:3735. [PubMed: 11073688]
11. a Bernardo PH, Chai CLL, Elix JA. *Tetrahedron Lett.* 2002; 43:2939. b Abe T, Ikeda T, Yanada R, Ishikura M. *Org. Lett.* 2011; 13:3356. [PubMed: 21627066] c Bhosale SM, Gawade RL, Puranik VG, Kusrurkar RS. *Tetrahedron Lett.* 2012; 53:2894.
12. a Sissouma D, Collet SC, Guingant AY. *Synlett.* 2004:2612. b Sissouma D, Maingot L, Collet S, Guingant A. *J. Org. Chem.* 2006; 71:8384. [PubMed: 17064009]
13. a Bernardo PH, Chai CL. *J. Org. Chem.* 2003; 68:8906. [PubMed: 14604361] b Ramkumar N, Nagarajan R. *J. Org. Chem.* 2014; 79:736. [PubMed: 24372379]

14. a Bernardo PH, Chai CL, Heath GA, Mahon PJ, Smith GD, Waring P, Wilkes BA. *J. Med. Chem.* 2004; 47:4958. [PubMed: 15369400] b Bennasar ML, Roca T, Ferrando F. *Org. Lett.* 2006; 8:561. [PubMed: 16468711] c Ramkumar N, Nagarajan R. *J. Org. Chem.* 2013; 78:2802. [PubMed: 23421392]
15. a Zhang X, Xu H, Zhang X, Voruganti S, Murugesan S, Nadkarni DH, Velu SE, Wang MH, Wang W, Zhang R. *Marine drugs.* 2012; 10:1138. [PubMed: 22822362] b Nadkarni DH, Wang F, Wang W, Rayburn ER, Ezell SJ, Murugesan S, Velu SE, Zhang R. *Med. Chem. (Shariqah (United Arab Emirates)).* 2009; 5:227. c Wang W, Rayburn ER, Velu SE, Nadkarni DH, Murugesan S, Zhang R. *Clin. Cancer Res.* 2009; 15:3511. [PubMed: 19451594] d Chen T, Xu Y, Guo H, Liu Y, Hu P, Yang X, Li X, Ge S, Velu SE, Nadkarni DH, Wang W, Zhang R, Wang H. *PloS one.* 2011; 6:e20729. [PubMed: 21673964]
16. Tseng C-M, Wu Y-L, Chuang C-P. *Tetrahedron.* 2004; 60:12249.
17. a Iqbal J, Bhatia B, Nayyar NK. *Chem. Rev.* 1994; 94:519. b Tseng C-C, Wu Y-L, Chuang C-P. *Tetrahedron.* 2002; 58:7625. c Chuang C-P, Wu Y-L. *Tetrahedron Lett.* 2001; 42:1717. d Chuang C-P, Tsai AI. *Tetrahedron.* 2007; 63:11911. e Wu Y-L, Chuang C-P, Lin P-Y. *Tetrahedron.* 2001; 57:5543.
18. Patai, S.; Rappoport, Z. *The Chemistry of Functional Groups: The Chemistry of The Quinoid Compounds.* Wiley; New York: 1988.
19. Murugesan S, Nadkarni DH, Velu SE. *Tetrahedron Lett.* 2009; 50:3074.
20. Nadkarni DH, Murugesan S, Velu SE. *Tetrahedron.* 2013; 69:4105. [PubMed: 23956468]
21. Kurz ME, Baru V, Nguyen PN. *J. Org. Chem.* 1984; 49:1603.

Figure 1.
Calothrixin A and B and the three moieties present in them

Scheme 1.
Retrosynthetic analysis of calothrixin B

Scheme 2.
Synthesis of intermediate quinone **5**

Scheme 3.
Conversion of quinone **5** to calothrixin A and B

Scheme 4.

Mechanism of oxidative radical reaction of 2-cyclohexenone with aminophenanthridinedione.